In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

Biogen’s late-stage lupus candidates may not have crossed the FDA finish line yet, but the company has already hit the ground ...

The appointments are “a direct response to where our clients need us most,” Michael Maslansky, CEO of m+p, said in a ...

With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping ...

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across ...

Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis (EoE) as ...

On Wednesday, the U.S. Court of Appeals for the Fifth Circuit affirmed (PDF) a previous ruling in district court rebuffing ...

The Trump administration looks set to unveil a new slate of most favored nation (MFN) drug pricing deals with several ...

RevMed’s leadership, too, highlighted the significance of Rasonque’s approval in a call with investors yesterday.